Skip to main content
. Author manuscript; available in PMC: 2010 Jul 15.
Published in final edited form as: Biol Psychiatry. 2009 Feb 27;66(2):185–190. doi: 10.1016/j.biopsych.2009.01.029

Table 2.

Counts and Severity Ratings of Treatment Emergent Symptomsa During 1-Week Medication Lead-in Period (Days 1–8)

Varenicline 2 mg/day (n = 10) Placebo 0 mg/day (n = 10)
Any Adverse Event 3 4
Nausea 1 (minimal) 0
Sleep Difficulties 1 (minimal) 4 (minimal)
Abnormal Dreams 1 (minimal) 1 (minimal)
Constipation 0 2 (minimal)
Flatulence 0 1 (mild)
Vomiting 0 1 (minimal)
a

More than 5% and twice the rate seen in placebo-treated patients for smoking cessation; frequency counts do not differ by medication condition.